The Role of Surgery and Adjuvants to Survival in Pagetic Osteosarcoma
- 1 November 2010
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Orthopaedics & Related Research
- Vol. 468 (11), 2962-2968
- https://doi.org/10.1007/s11999-010-1473-7
Abstract
Osteosarcoma is a rare complication of Paget’s disease with a very poor prognosis. Treatment is controversial: the older age of the patients affected by Paget’s disease may limit the use of chemotherapy and axial involvement may limit the practicality of surgery. The purposes of this study are (1) to report the survival in patients treated for osteosarcoma in Paget’s disease; (2) to identify correlations between type of treatment and survival comparing our data with those in the literature; (3) to determine if the extent of Paget’s disease and risk of malignant transformation are associated; (4) to assess if prognosis is related with site; and (5) to identify the variations of histologic subtypes of these osteosarcomas. We retrospectively reviewed the medical records of 26 patients treated between 1961 and 2006 who had bone sarcoma arising from a site of Paget’s disease. Twenty two of the 26 patients had surgery. In six surgery only was performed; three had surgery, adjuvant chemotherapy, and radiotherapy; one surgery and radiotherapy; 12 underwent surgery and chemotherapy, adjuvant in 10 patients and neoadjuvant in two; two had only radiotherapy and two had only chemotherapy. We performed survival analyses between various combinations of treatment. At last followup four patients had no evidence of disease (NED) at a minimum followup of 42.6 months (mean, 139 months; range, 42.6–257.4 months) and 22 died with disease (DWD) at a minimum time of 1 month (mean, 20.2 months; range, 1–84 months). One of the six patients (11%) treated with surgery only had NED at 10 years; the other five died from disease at a mean of 30 months. Three of 12 patients (25%) treated with surgery and chemotherapy are NED at a mean followup of 12 years; nine died of disease at a mean of 24 months. All patients treated without surgery died at a mean of 7.5 months (range, 1–13.7 months). Despite improvements in surgery and medical treatments the prognosis remains poor in patients with Paget’s sarcoma. Level IV, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.Keywords
This publication has 41 references indexed in Scilit:
- Paget Disease of BoneJCR: Journal of Clinical Rheumatology, 2008
- Osteosarcoma in Paget's Disease of BoneJournal of Bone and Mineral Research, 2006
- A Clinical Approach to Diagnosis and Management of Paget's Disease of BoneJournal of Bone and Mineral Research, 2001
- Paget′s Osteosarcoma — no Cure in SightSarcoma, 1999
- Simultaneous Multifocal Sarcomatous Degeneration in Paget??s Disease of Bone A HypothesisPublished by Ovid Technologies (Wolters Kluwer Health) ,1983
- Paget's disease of bone in 14 British towns.BMJ, 1977
- On a Form of Chronic Inflammation of Bones (Osteitis Deformans)Published by Ovid Technologies (Wolters Kluwer Health) ,1966
- Bone sarcoma complicating Paget's disease.A report of 3 cases with long survivalCancer, 1961
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958
- Über Ostitis deformans PagetVirchows Archiv, 1932